VINCIT: A virus-incorporated biomaterial niche enables spatially controlled in vivo CAR T cell engineering
In the authors' words
In vivo generation of chimeric antigen receptor (CAR) T cells could bypass the complex manufacturing required for conventional cell therapies, but systemic gene delivery remains limited by off target exposure and inefficient access to target immune cells. Here, we develop VINCIT (Virus Incorporated Niche for Cellular ImmunoTherapy), an injectable nanofiber hydrogel composite that establishes a localized immune-engineering niche for CAR T cell generation in vivo. VINCIT spatially retains viral vectors while recruiting endogenous immune cells, enabling local transduction of T cells, after which the engineered T cells enter the circulation. VINCIT spatially confines transgene expression compared with intravenous viral delivery and markedly enhances T cell transduction compared with subcutaneously injected free virus. VINCIT is compatible with both adeno-associated and lentiviral vectors, and CAR T cells generated in vivo exhibit antigen-specific effector responses and mediate CD19+ B cell depletion. In a humanized mouse model of lymphoma, a single VINCIT administration produces sustained tumor control and extends median survival from 32 to 110 days. Mechanistically, efficient CAR T cell generation requires coordinated interactions among multiple immune populations, with neutrophil depletion markedly reducing cellular recruitment and subsequent T cell programming. These findings establish a localized biomaterial niche for spatially controlled in vivo immune cell engineering.
In plain words AI summary
The authors developed VINCIT, an injectable gel that creates a local site for engineering CAR T cells inside the body. VINCIT keeps viral vectors in one place, recruits immune cells, and lets engineered T cells enter the bloodstream after local modification. Compared to injecting virus into a vein, VINCIT limits gene expression to the local area and improves T cell modification. In a humanized mouse lymphoma model, one VINCIT dose extended median survival from 32 days to 110 days. Neutrophil depletion greatly reduced cell recruitment and T cell programming, showing that multiple immune cell types must work together.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Thursday, November 19. bioRxiv. Preprint, not yet peer-reviewed.